234 related articles for article (PubMed ID: 33113415)
1. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.
Zhou J; Yu LZ; Fan YL; Guo CH; Lv XM; Zhou ZY; Huang HD; Miao DD; Zhang SP; Li XY; Zhao PP; Liu XP; Hu WH; Zhang C
Eur J Med Chem; 2023 Jan; 245(Pt 1):114860. PubMed ID: 36370550
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
[TBL] [Abstract][Full Text] [Related]
4. Discovery of IDO1 and DNA dual targeting antitumor agents.
Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
Org Biomol Chem; 2017 Dec; 15(47):9992-9995. PubMed ID: 29177308
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.
Qian J; Xu Z; Meng C; Liu J; Hsu PL; Li Y; Zhu W; Yang Y; Morris-Natschke SL; Lee KH; Zhang Y; Ling Y
Eur J Med Chem; 2020 Oct; 204():112610. PubMed ID: 32736231
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
Cui G; Lai F; Wang X; Chen X; Xu B
Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors.
Zhong Y; Liu J; Cheng X; Zhang H; Zhang C; Xia Z; Wu Z; Zhang L; Zheng Y; Gao Z; Jiang Z; Wang Z; Huang D; Lu Y; Jiang F
Bioorg Chem; 2021 Apr; 109():104736. PubMed ID: 33640630
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel derivatives of dithiodiglycolic acid prepared via oxidative coupling of thiols.
Bakulina O; Bannykh A; Jovanović M; Domračeva I; Podolski-Renić A; Žalubovskis R; Pešić M; Dar'in D; Krasavin M
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):665-671. PubMed ID: 30746961
[TBL] [Abstract][Full Text] [Related]
9. Novel Phenylmethylenecyclohexenone Derivatives as Potent TrxR Inhibitors Display High Antiproliferative Activity and Induce ROS, Apoptosis, and DNA Damage.
Wang X; Qian J; Zhu P; Hua R; Liu J; Hang J; Meng C; Shan W; Miao J; Ling Y
ChemMedChem; 2021 Feb; 16(4):702-712. PubMed ID: 33085980
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
[TBL] [Abstract][Full Text] [Related]
11. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.
Coluccia A; Passacantilli S; Famiglini V; Sabatino M; Patsilinakos A; Ragno R; Mazzoccoli C; Sisinni L; Okuno A; Takikawa O; Silvestri R; La Regina G
J Med Chem; 2016 Nov; 59(21):9760-9773. PubMed ID: 27690429
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.
Chen S; Guo W; Liu X; Sun P; Wang Y; Ding C; Meng L; Zhang A
Eur J Med Chem; 2019 Oct; 179():38-55. PubMed ID: 31233921
[TBL] [Abstract][Full Text] [Related]
13. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
14. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Zhang P; Shi L; Zhang T; Hong L; He W; Cao P; Shen X; Zheng P; Xia Y; Zou P
Cell Oncol (Dordr); 2019 Dec; 42(6):847-860. PubMed ID: 31493144
[TBL] [Abstract][Full Text] [Related]
15. Identification of phenazine analogue as a novel scaffold for thioredoxin reductase I inhibitors against Hep G2 cancer cell lines.
Liao J; Wang L; Wu Z; Wang Z; Chen J; Zhong Y; Jiang F; Lu Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1158-1163. PubMed ID: 31179772
[TBL] [Abstract][Full Text] [Related]
16. Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR.
Yan J; Xu Y; Jin X; Zhang Q; Ouyang F; Han L; Zhan M; Li X; Liang B; Huang X
Eur J Med Chem; 2022 Jan; 227():113897. PubMed ID: 34649064
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of flavonoids isolated from
Kwon M; Ko SK; Jang M; Kim GH; Ryoo IJ; Son S; Ryu HW; Oh SR; Lee WK; Kim BY; Jang JH; Ahn JS
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1481-1488. PubMed ID: 31423846
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of novel methylenecyclohexenone derivatives as TrxR inhibitors in suppressing the proliferation and metastasis of human cancer cells.
Meng C; Qian J; Xu Z; Liu J; Shan W; Zhu P; Zhu W; Miao J; Ling CC; Ling Y
Bioorg Chem; 2020 Dec; 105():104360. PubMed ID: 33074118
[TBL] [Abstract][Full Text] [Related]
19. The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors.
Fallarini S; Bhela IP; Aprile S; Torre E; Ranza A; Orecchini E; Panfili E; Pallotta MT; Massarotti A; Serafini M; Pirali T
ChemMedChem; 2021 Nov; 16(22):3439-3450. PubMed ID: 34355531
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer.
Zou P; Xia Y; Ji J; Chen W; Zhang J; Chen X; Rajamanickam V; Chen G; Wang Z; Chen L; Wang Y; Yang S; Liang G
Cancer Lett; 2016 May; 375(1):114-126. PubMed ID: 26963494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
